ImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer
I'm PortAI, I can summarize articles.
ImmunityBio, Inc. announced that its treatment ANKTIVA® combined with BCG achieved a 96% three-year bladder cancer-specific survival rate in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer. The study, published in The Journal of Urology, also showed favorable outcomes in disease-free and progression-free survival, and high rates of cystectomy avoidance. Safety data indicated a 3% incidence of grade 3 treatment-related adverse events. ANKTIVA is approved in the U.S., U.K., and conditionally in the EU for BCG-unresponsive NMIBC.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments